

# Mondher Toumi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1408355/mondher-toumi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

1,859  
citations

24  
h-index

38  
g-index

133  
ext. papers

2,346  
ext. citations

3.5  
avg, IF

5.18  
L-index

| #   | Paper   | IF  | Citations |
|-----|---|-----|-----------|
| 119 | Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. <i>British Journal of Psychiatry</i> , <b>2007</b> , 191, 30-7   | 5.4 | 248       |
| 118 | Burden on caregivers of people with schizophrenia: comparison between Germany and Britain. <i>British Journal of Psychiatry</i> , <b>2007</b> , 190, 333-8  | 5.4 | 93        |
| 117 | Gene therapies development: slow progress and promising prospect. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1265293  | 3.7 | 68        |
| 116 | Advanced therapy medicinal products: current and future perspectives. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,  | 3.7 | 65        |
| 115 | A prospective study of Quality of life in schizophrenia in three European countries. <i>Schizophrenia Research</i> , <b>2007</b> , 93, 194-202  | 3.6 | 54        |
| 114 | The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2005</b> , 40, 707-17  | 4.5 | 54        |
| 113 | Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. <i>Journal of Nervous and Mental Disease</i> , <b>2008</b> , 196, 87-94  | 1.8 | 47        |
| 112 | Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2009</b> , 119, 22-8   | 6.5 | 44        |
| 111 | Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. <i>Value in Health</i> , <b>2018</b> , 21, 493-500                     | 3.3 | 41        |
| 110 | Access to orphan drugs in Europe: current and future issues. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2012</b> , 12, 23-9   | 2.2 | 40        |
| 109 | Key drivers for market penetration of biosimilars in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1272308   | 3.7 | 38        |
| 108 | Overview of external reference pricing systems in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3,  | 3.7 | 38        |
| 107 | Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. <i>Psychiatry Research</i> , <b>2016</b> , 239, 301-9 | 3.7 | 38        |
| 106 | Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. <i>BMC Health Services Research</i> , <b>2011</b> , 11, 259  | 2.9 | 36        |
| 105 | Measuring the health-related quality of life in young children: how far have we come?. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1618661   | 3.7 | 34        |
| 104 | Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. <i>Value in Health</i> , <b>2019</b> , 22, 661-668  | 3.3 | 33        |
| 103 | Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC). <i>Psychological Medicine</i> , <b>2008</b> , 38, 591-7       | 6.9 | 32        |

|     |  |     |    |
|-----|--|-----|----|
| 102 | Sipuleucel-T (Provenge(®)) -Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. <i>BioDrugs</i> , <b>2015</b> , 29, 301-7   | 7.9 | 31 |
| 101 | Comparison of NITAG policies and working processes in selected developed countries. <i>Vaccine</i> , <b>2015</b> , 33, 3-11  | 4.1 | 31 |
| 100 | Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 655  | 4   | 31 |
| 99  | Characteristics of doctor-shoppers: a systematic literature review. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1595953   | 3.7 | 28 |
| 98  | Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1307315   | 3.7 | 25 |
| 97  | Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC). <i>European Psychiatry</i> , <b>2009</b> , 24, 216-24   | 6   | 25 |
| 96  | Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1299665  | 3.7 | 24 |
| 95  | Managed Entry Agreements: Policy Analysis From the European Perspective. <i>Value in Health</i> , <b>2020</b> , 23, 425-433  | 3.3 | 24 |
| 94  | Funding breakthrough therapies: A systematic review and recommendation. <i>Health Policy</i> , <b>2018</b> , 122, 217-229  | 3.2 | 22 |
| 93  | Filling the gap in CNS drug development: evaluation of the role of drug repurposing. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1299833  | 3.7 | 21 |
| 92  | Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 27-36                              | 2.4 | 21 |
| 91  | Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1574541 | 3.7 | 21 |
| 90  | A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3,                 | 3.7 | 18 |
| 89  | Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , <b>2015</b> , 230, 860-6   | 9.9 | 18 |
| 88  | Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC). <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2007</b> , 42, 617-22   | 4.5 | 18 |
| 87  | A comparative study of orphan drug prices in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1297886  | 3.7 | 17 |
| 86  | A prospective study of health care resource utilisation and selected costs of schizophrenia in France. <i>BMC Health Services Research</i> , <b>2012</b> , 12, 269-76  | 2.9 | 17 |
| 85  | Chinese guidelines related to novel coronavirus pneumonia. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1818446  | 3.7 | 17 |

|    |   |      |    |
|----|---|------|----|
| 84 | New drug regulations in France: what are the impacts on market access? Part 1 - Overview of new drug regulations in France. <i>Journal of Market Access &amp; Health Policy</i> , <b>2013</b> , 1,  | 3.7  | 16 |
| 83 | Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. <i>BMC Psychiatry</i> , <b>2011</b> , 11, 24  | 4.2  | 16 |
| 82 | Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1344088   | 3.7  | 14 |
| 81 | The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate. <i>Applied Health Economics and Health Policy</i> , <b>2017</b> , 15, 5-11   | 3.4  | 14 |
| 80 | The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , <b>2021</b> , 198, 230-237   | 4    | 14 |
| 79 | The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1369817  | 3.7  | 13 |
| 78 | Regenerative medicine regulatory policies: A systematic review and international comparison. <i>Health Policy</i> , <b>2020</b> , 124, 701-713  | 3.2  | 13 |
| 77 | Clinical management and associated costs for moderate and severe Alzheimer® disease in urban China: a Delphi panel study. <i>Translational Neurodegeneration</i> , <b>2015</b> , 4, 15  | 10.3 | 13 |
| 76 | Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence. <i>Applied Health Economics and Health Policy</i> , <b>2011</b> , 9, 209-15   | 3.4  | 13 |
| 75 | Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 27-36 | 2.2  | 13 |
| 74 | Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. <i>Influenza and Other Respiratory Viruses</i> , <b>2017</b> , 11, 543-555                       | 5.6  | 12 |
| 73 | Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1298190   | 3.7  | 11 |
| 72 | Health economic evaluation of gene replacement therapies: methodological issues and recommendations. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1822666   | 3.7  | 11 |
| 71 | Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,  | 3.7  | 11 |
| 70 | Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 785-792   | 2.5  | 10 |
| 69 | Determinants of orphan drugs prices in France: a regression analysis. <i>Orphanet Journal of Rare Diseases</i> , <b>2017</b> , 12, 75   | 4.2  | 10 |
| 68 | Current process and future path for health economic assessment of pharmaceuticals in France. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3,   | 3.7  | 10 |
| 67 | Economic burden for Alzheimer® disease in China from 2010 to 2050: a modelling study. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1667195  | 3.7  | 9  |

|    |   |     |   |
|----|---|-----|---|
| 66 | Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1758390   | 3.7 | 8 |
| 65 | Drug repurposing in pharmaceutical industry and its impact on market access: market access implications. <i>Journal of Market Access &amp; Health Policy</i> , <b>2014</b> , 2,   | 3.7 | 8 |
| 64 | Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1283105  | 3.7 | 7 |
| 63 | Chinese Guidelines Related to Novel Coronavirus Pneumonia   |     | 7 |
| 62 | Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties. <i>Open Journal of Medical Psychology</i> , <b>2014</b> , 03, 141-156  | 0.4 | 7 |
| 61 | Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 399-415  | 8.8 | 7 |
| 60 | Memantine for treatment of moderate or severe Alzheimer® disease patients in urban China: clinical and economic outcomes from a health economic model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2015</b> , 15, 565-78   | 2.2 | 6 |
| 59 | Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1867-1872 | 2.5 | 6 |
| 58 | Healthcare resource use in schizophrenia, EuroSC findings. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1372027   | 3.7 | 6 |
| 57 | Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. <i>Cardiovascular Therapeutics</i> , <b>2020</b> , 2020, 3057168  | 3.3 | 6 |
| 56 | Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 119  | 5.7 | 6 |
| 55 | Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,   | 3.7 | 6 |
| 54 | The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling. <i>Psychological Medicine</i> , <b>2020</b> , 50, 566-574  | 6.9 | 6 |
| 53 | Stigma in visible skin diseases - a literature review and development of a conceptual model. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1493-1504  | 4.6 | 6 |
| 52 | Systematic review of pharmacoeconomic models for schizophrenia. <i>Journal of Market Access &amp; Health Policy</i> , <b>2018</b> , 6, 1508272  | 3.7 | 5 |
| 51 | Quantifying the persisting orphan-drug shortage public health crisis in the United States. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1269473   | 3.7 | 5 |
| 50 | National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3,  | 3.7 | 5 |
| 49 | Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. <i>Cell &amp; Gene Therapy Insights</i> , <b>2019</b> , 5, 1043-1059  | 2.3 | 5 |

|    |   |     |   |
|----|---|-----|---|
| 48 | No correlation between the prices of oncology orphan drugs in the US and their patient population sizes. <i>Journal of Cancer Policy</i> , <b>2017</b> , 14, 1-4  | 1   | 4 |
| 47 | Non-profit drug research and development: the case study of Genethon. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1545514  | 3.7 | 4 |
| 46 | Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3, 25682  | 3.7 | 4 |
| 45 | Fixing the price of the orphan drug Siklos: the Council of State takes over the decision. <i>European Journal of Health Law</i> , <b>2014</b> , 21, 505-15  | 0.2 | 4 |
| 44 | Current state of developing advanced therapies for rare diseases in the European Union. <i>Expert Opinion on Orphan Drugs</i> , <b>2020</b> , 8, 417-429  | 1.1 | 4 |
| 43 | Factors influencing the COVID-19 daily deaths peak across European countries. <i>Public Health</i> , <b>2021</b> , 194, 135-142   | 4   | 4 |
| 42 | Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 281-304 | 3.4 | 4 |
| 41 | Health related quality of life in patients having schizophrenia negative symptoms - a systematic review. <i>Journal of Market Access &amp; Health Policy</i> , <b>2018</b> , 6, 1517573   | 3.7 | 4 |
| 40 | Primary cesarean delivery rate: Potential impact of a checklist. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , <b>2018</b> , 47, 419-424   | 1.9 | 4 |
| 39 | Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1648973                          | 3.7 | 3 |
| 38 | Non-profit Drug Research and Development at a Crossroads. <i>Pharmaceutical Research</i> , <b>2018</b> , 35, 52   | 4.5 | 3 |
| 37 | On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe. <i>Journal of Market Access &amp; Health Policy</i> , <b>2021</b> , 9, 2002008  | 3.7 | 3 |
| 36 | Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment.. <i>Frontiers in Public Health</i> , <b>2022</b> , 10, 773629  | 6   | 3 |
| 35 | The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. <i>Drug Discovery Today</i> , <b>2021</b> , 26, 2269-2281   | 8.8 | 3 |
| 34 | Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,   | 3.7 | 3 |
| 33 | Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 29-44           | 3.4 | 3 |
| 32 | Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration. <i>Journal of Market Access &amp; Health Policy</i> , <b>2018</b> , 6, 1433426   | 3.7 | 2 |
| 31 | Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 750742                                 | 5.6 | 2 |



|    |  |     |   |
|----|--|-----|---|
| 30 | The diversity in regenerative medicines regulations in Europe, USA and Japan. <i>Cell &amp; Gene Therapy Insights</i> , <b>2019</b> , 5, 1031-1042   | 2.3 | 2 |
| 29 | Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. <i>Health Policy</i> , <b>2021</b> , 125, 1550-1556   | 3.2 | 2 |
| 28 | Oncology from an HTA and Health Economic Perspective. <i>Recent Results in Cancer Research</i> , <b>2019</b> , 213, 25-38  | 1.5 | 2 |
| 27 | Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1775933   | 3.7 | 2 |
| 26 | Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. <i>Journal of Market Access &amp; Health Policy</i> , <b>2016</b> , 4,   | 3.7 | 2 |
| 25 | Orphan Drugs in Oncology. <i>Recent Results in Cancer Research</i> , <b>2019</b> , 213, 109-142  | 1.5 | 2 |
| 24 | Patient-reported outcome claims in European and United States orphan drug approvals. <i>Journal of Market Access &amp; Health Policy</i> , <b>2018</b> , 6, 1542920  | 3.7 | 2 |
| 23 | Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 1145-1158                          | 2.2 | 2 |
| 22 | Why "American Patients First" is likely to raise drug prices outside of the United States. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1650596  | 3.7 | 1 |
| 21 | President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First. <i>Journal of Market Access &amp; Health Policy</i> , <b>2019</b> , 7, 1579597   | 3.7 | 1 |
| 20 | Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1355202   | 3.7 | 1 |
| 19 | A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1372026                                  | 3.7 | 1 |
| 18 | Second opinions, multiple physician appointments, and overlapping prescriptions in the paediatric population: A systematic literature review. <i>Journal of Evaluation in Clinical Practice</i> , <b>2020</b> , 26, 1761-1767              | 2.5 | 1 |
| 17 | Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 754482 | 6   | 1 |
| 16 | Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. <i>Health Policy</i> , <b>2021</b> , 126, 49-49   | 3.2 | 1 |
| 15 | An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models. <i>Journal of Market Access &amp; Health Policy</i> , <b>2021</b> , 9, 2002006   | 3.7 | 1 |
| 14 | Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials  |     | 1 |
| 13 | Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled Trials. <i>Recent Results in Cancer Research</i> , <b>2019</b> , 213, 57-65  | 1.5 | 1 |

|    |   |     |   |
|----|---|-----|---|
| 12 | Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment. <i>Recent Results in Cancer Research</i> , <b>2019</b> , 213, 39-55  | 1.5 | 1 |
| 11 | Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs. <i>Psychological Medicine</i> , <b>2021</b> , 1-8                                   | 6.9 | 1 |
| 10 | Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 1280-1289   | 2.4 | 0 |
| 9  | Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 929-939  | 3.2 | 0 |
| 8  | Gene therapy randomised clinical trials in Europe - a review paper of methodology and design. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1847808  | 3.7 | 0 |
| 7  | A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1809236  | 3.7 | 0 |
| 6  | Point-of-Care test screening versus Case finding for paediatric coeliac disease: A pragmatic study in primary care. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>2021</b> , 110, 337-339          | 3.1 | 0 |
| 5  | Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. <i>Journal of Market Access &amp; Health Policy</i> , <b>2021</b> , 9, 1887664                                 | 3.7 | 0 |
| 4  | Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvements. <i>Vaccine</i> , <b>2021</b> , 39, 5706-5718   | 4.1 | 0 |
| 3  | About the advantages and disadvantages of discrete-event simulation for health economic analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2016</b> , 16, 651-652                           | 2.2 |   |
| 2  | Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. <i>Regenerative Medicine</i> , <b>2021</b> , 16, 733-755   | 2.5 |   |
| 1  | Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study.. <i>Schizophrenia Research</i> , <b>2022</b> , 244, 21-28 | 3.6 |   |